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Abstract
 
CpG oligodeoxynucleotides (ODN) have potent effects on innate and adaptive cellular immune
responses. In this report, the ability of CpG ODN to confer long-term immunity and protec-
tion when used as a vaccine adjuvant with a clinical grade of leishmanial antigen, autoclaved
 
Leishmania major
 
 (ALM), or a recombinant leishmanial protein was studied. In two different
mouse models of 
 
L. major
 
 infection, vaccination with ALM plus CpG ODN was able to con-
trol infection and markedly reduce lesion development in susceptible BALB/c and resistant
C57BL/6 (B6) mice, respectively, up to 12 wk after immunization. Moreover, B6 mice immu-
nized with ALM plus CpG ODNs were still protected against infectious challenge even 6 mo
after vaccination. In terms of immune correlates of protection, ALM plus CpG ODN-vacci-
nated mice displayed 
 
L. major
 
–specific T helper cell 1 and CD8
 
  
 
responses. In addition, com-
plete protection was markedly abrogated in mice depleted of CD8
 
  
 
T cells at the time of vacci-
nation. Similarly, mice vaccinated with a recombinant leishmanial protein plus CpG ODN also
had long-term protection that was dependent on CD8
 
  
 
T cells in vivo. Together, these data
demonstrate that CpG ODN, when used as a vaccine adjuvant with either a recombinant pro-
tein or heat-killed leishmanial antigen, can induce long-term protection against an intracellular
infection in a CD8-dependent manner.
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Introduction
 
The induction and maintenance of cellular immune re-
sponses is the primary goal of vaccines for a variety of intra-
cellular infections including 
 
Mycobacterium tuberculosis
 
, 
 
Plas-
modium
 
 species, and 
 
Leishmania major
 
. Effective primary
immunity against 
 
L. major
 
, the causative agent of cutaneous
leishmaniasis, is known to require IL-12–dependent pro-
duction of IFN-
 
  
 
from CD4
 
  
 
T cells (1–3). Resistant
C57BL/6 (B6)
 
* 
 
mice develop protective Th1 responses
that control infection, whereas susceptible BALB/c mice
are unable to control infection due to an aberrant Th2 re-
sponse produced by a restricted population of V
 
 
 
4V
 
 
 
8
CD4
 
  
 
T cells (4, 5). The treatment of BALB/c mice with
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IL-12 protein or neutralizing Ab to IL-4 at the time of in-
fection has been shown to shift the immune response to a
Th1 profile and prevent susceptibility to infection (1, 6).
This ability to alter Th responses in BALB/c mice and to
assess the functionality of these responses with a biologic
correlate has made this a useful model for vaccine develop-
ment against diseases requiring Th1 immunity.
Previous vaccine studies in BALB/c mice have demon-
strated that long-lasting control (up to 12 wk after vaccina-
tion) of 
 
L. major
 
 infection can result from vaccination with
plasmid DNA encoding of a specific leishmanial Ag (7). In
contrast, vaccination with either soluble leishmanial Ag
(SLA) or a recombinant leishmanial protein plus IL-12 pro-
tein conferred short-term (4, 8) but not long-term protec-
tion (9). However, if leishmanial protein plus IL-12 pro-
tein–vaccinated mice were repeatedly boosted with IL-12
protein, control of infection was better sustained (10). Fur-
thermore, mice vaccinated with leishmanial protein plus
IL-12 DNA also had long-term Th1 immunity and protec-
tion (9). These data suggested that persistent IL-12 is neces-
sary to sustain immunity sufficient for protection against 
 
L.
major
 
 when using a protein vaccine. Similarly, in a low dose
challenge model that more closely mimics the human dis-
ease in terms of route and dose of infection, vaccination
with DNA again has been shown superior to vaccination
with leishmanial protein plus IL-12 in protecting against le-
sion development and parasite burden in resistant B6 mice
challenged 12 wk after immunization (11, 12).
To better understand why protein and DNA vaccines
have varying efficacy in the Leishmania mouse model, the
immune correlates of protection were analyzed. As previ-
ously noted, protein vaccines that primarily elicit CD4
 
  
 
T
cell responses require persistent IL-12 for control of infec-
tion in this model (10). In contrast, DNA vaccination in-
duces Ag-specific CD4
 
  
 
and CD8
 
  
 
T cells that are required
for long-term immunity (7, 13). In addition, plasmid DNA
vaccination may offer an advantage over protein vaccines
by inducing a qualitatively and/or quantitatively different
type of cellular immune response through specific immu-
nostimulatory CpG sequences contained within the vector
(14, 15). In this regard, nucleotide sequences containing
these CpG motifs have been synthesized and studied as
possible immune adjuvants for diseases requiring Th1
immune responses (16, 17). CpG oligodeoxynucleotides
(ODN) have been shown to stimulate macrophages and
dendritic cells (DC) to synthesize several cytokines includ-
ing IL-12, IL-18, TNF-
 
 
 
, IFN-
 
 
 
, IFN-
 
 
 
, and IFN-
 
 
 
 and
to up-regulate costimulatory molecules such as CD40 and
MHC class II (18–20). The range and level of cytokine
production vary according to each ODN sequence and its
particular modifications (21). Moreover, CpG ODN have
been shown to activate DC, leading to the presentation of
soluble protein to class I–restricted T cells and the induc-
tion of CTL responses (20, 22, 23). This ability of CpG
ODN to induce both innate and adaptive cellular immune
responses has made it a potential treatment and/or prophy-
lactic vaccine adjuvant, respectively, for diseases requiring
cellular immunity.
 
In studying the role of CpG ODN as a prophylactic vac-
cine adjuvant, leishmanial proteins plus CpG ODN have
been reported to confer some protection after a challenge
with 
 
L. major
 
 (24, 25)
 
.
 
 In addition, susceptible BALB/c
mice treated only with CpG ODN up to 2 wk before or
20 d after infection with 
 
L. major
 
 were able to control in-
fection (26, 27). It is notable that in the latter study, a Th1
response was induced in the course of an ongoing Th2 re-
sponse in mice treated with CpG ODN after infection
(27). In striking contrast, treatment of susceptible BALB/c
mice with IL-12 protein alone was only sufficient to con-
trol infection if administered at the time of infection with
 
L. major
 
 and continued for up to 1 wk (1). Together, these
data suggest that CpG ODN is more potent and durable
than IL-12 protein in terms of immune and biologic effects
in susceptible BALB/c mice after infection with 
 
L. major.
 
In view of the potent in vivo effects on the cellular im-
mune response elicited by CpG ODN, the data presented
here determined whether mice vaccinated with CpG
ODN and either a clinical grade of autoclaved (heat-killed)
 
L. major
 
 (ALM) Ag or recombinant leishmanial protein had
sustained immunity and protection in two different mouse
models of 
 
L. major
 
 infection.
 
Materials and Methods
 
Mice.
 
Female BALB/c mice were purchased from Taconic
Farms, Inc., and female B6 mice were purchased from the Divi-
sion of Cancer Treatment, National Cancer Institute. All mice
were maintained in the National Institute of Allergy and Infectious
Diseases Animal Care Facility or Vaccine Research Center Animal
Care Facility (Bethesda, MD) under pathogen-free conditions.
 
ODN.
 
Phosphorothioate-modified ODN sequence 1826
containing two CpG motifs (underlined: TCCATGACGTTC-
CTGACGTT) was provided by Coley Pharmaceutical Group
and used in most experiments. ODN sequence 1982 was used as
a control in some experiments (TCCAGGACTTCTCTCAG
GTT). The ODN contained endotoxin levels 
 
 
 
0.1 EU/mg us-
ing the limulus amebocyte lysis assay (Associates of Cape Cod,
Inc.). For the 6-mo challenge study in B6 mice, CpG ODN were
synthesized at the Center for Biologics Evaluation and Research
Core Facility (Bethesda, MD). Sequences were TCAACGTTGA
and GCTAGACGTTAGCGT.
 
Immunization.
 
BALB/c and B6 mice were injected subcuta-
neously in their hind footpad with either 50 
 
 
 
g ALM prepared
from whole cell, heat-killed 
 
L. major
 
 promastigotes or 25 
 
 
 
g of a
recombinant leishmanial protein containing three Ag: LmSTI1
(28), TSA (29), and LeIF (30). This three-Ag leishmanial protein
vaccine is referred to as Trifusion (Corixa Corporation). ALM is
a clinical grade reagent and contained 
 
 
 
10 EU/dose. Trifusion
protein contained levels of endotoxin at the lower limits of de-
tection in the limulus lysate assay. ALM was given alone or with
1 
 
 
 
g recombinant IL-12 (Genetics Institute) or 50 
 
 
 
g CpG
ODN. Trifusion protein was given alone or with 25 
 
 
 
g CpG
ODN. Each injection was suspended in sterile PBS and given in a
volume of 50 
 
 
 
l. In some experiments, as a positive control, na-
ive BALB/c mice were treated with 1 
 
 
 
g neutralizing murine Ab
against IL-4 (clone 11B11; provided by W. Paul, NIH, Bethesda,
MD) 2 d before, and at the time of, infection. In other experi-
ments, as an additional positive control for long-term protection,
mice were vaccinated with a “cocktail” of DNA containing 33 
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g each of plasmid DNA encoding LACK Ag, LmSTI1 Ag, or
TSA Ag, combined for a total of 99 
 
 
 
g DNA/dose (11). In the
6-mo challenge study, B6 mice were vaccinated intradermally in
a volume of 10 
 
 
 
l into the ventral surface of the ear. In all exper-
iments, mice were boosted 2 wk after the initial injection into the
same site with their initial regimen. To determine the role of
CD8
 
  
 
T cells in mediating protection with ALM plus CpG
ODN or Trifusion protein plus CpG ODN, mice were treated
1 d before, and at the time of, each vaccination with 0.5 
 
 
 
g of a
rat Ig control Ab or rat anti–mouse CD8 Ab (2.43) that has been
shown to deplete 
 
 
 
95% of CD8
 
  
 
T cells and was sufficient to ab-
rogate protection to DNA vaccination in this model (7, 13). In
addition, treatment with anti-CD8 did not diminish the number
or function (e.g., IL-12 production) of CD11c
 
  
 
cells (13).
 
Infectious Challenge. L.  major 
 
clone V1 (MHOM/IL/80/
Friedlin) promastigotes were grown as previously described (11).
Infective stage promastigotes (metacyclics) of 
 
L. major
 
 were iso-
lated from stationary cultures (4–5 d old) by negative selection
using peanut agglutinin (Vector Laboratories). B6 mice were
challenged intradermally at 2 or 12 wk after vaccination in both
ears using 500 metacyclic promastigotes. In the 6-mo challenge
experiment, infection was done in the ear opposite to vaccina-
tion. The lesions were monitored by measuring the diameter of
the induration of the ear lesion with a metric caliper. BALB/c
mice were infected either 2 or 12 wk after the boost with 10
 
5
 
metacyclic promastigotes. Parasites were injected into the footpad
subcutaneously contralateral from the site of vaccination at a vol-
ume of 50 
 
 
 
l. Weekly footpad swelling measurements were re-
corded using a metric caliper.
 
Parasite Quantitation.
 
Parasite loads in the ears of B6 mice
were determined as previously described (11). The number of vi-
able parasites in each ear was determined from the highest dilu-
tion that promastigotes could be grown out after 7 d of incuba-
tion at 26
 
 
 
C. The number of parasites was also determined in the
local draining LN (popliteal) of BALB/c mice. The LN from
each mouse was recovered and mechanically dissociated using a
pellet pestle and then serially diluted as previously described. For
most experiments, ears or draining LN from at least three indi-
vidual mice were analyzed for parasite burden. Statistical analysis
was done as previously described (11).
 
Measurement of Leishmania-specific Production of IFN-
 
 
 
 from
CD4
 
  
 
T Cells after Infection.
 
4 wk after infection, draining LN
were harvested from different groups of vaccinated BALB/c
mice. The nodes from a minimum of three mice in each group
were pooled and then purified into CD4
 
  
 
T cell subpopulations
using magnetic-activated cell sorting columns (Miltenyi Biotec).
Flow cytometry confirmed 
 
 
 
95% purity of CD4
 
  
 
T lympho-
cytes. The cells were then plated in triplicate in a 96-well micro-
titer plate at 2 
 
  
 
10
 
5 
 
cells/200 
 
 
 
l and cultured with media, mac-
rophages (5 
 
  
 
10
 
4
 
), or macrophages plus
 
 L. major
 
. Macrophages
were obtained by intraperitoneal washings of naive BALB/c
mice and then pulsed with or without 
 
L. major
 
 before being
added to the CD4
 
  
 
T cell cultures. Supernatants were collected
48 h later and assessed for production of IFN-
 
  
 
by specific ELISA
(BD PharMingen). The lower limit of detection of IFN-
 
  
 
was
31.3 pg/ml.
 
Assessment of the Frequency of Leishmania-specific CD4
 
  
 
and
CD8
 
  
 
Cytokine-producing Cells after Vaccination.
 
6 mo after vac-
cination, B6 mice were injected in both ears with a combination
of living and killed Ag comprising 10
 
6 
 
metacyclic 
 
L. major
 
 pro-
mastigotes and 12.5 
 
 
 
g SLA prepared from 33 freeze-thawed sta-
tionary phase 
 
L. major
 
 promastigotes. 48 h later, three mice per
group were killed and cells from the local draining LN were ob-
tained as previously described. For intracellular staining of IFN-
 
 
 
,
cells were stimulated with DC or DC pulsed with 
 
L. major
 
 for 6 h
and then 10 
 
 
 
g/ml brefeldin A was added. The cells were cul-
tured for an additional 18 h and then fixed in 4% paraformalde-
hyde. Staining of surface and cytoplasmic markers was performed
as previously described (11). For each sample, at least 100,000
cells were analyzed.
 
Results
 
Vaccination with ALM plus CpG ODN Confers Durable
Protection Against L. major in BALB/c Mice.
 
In previous
reports, vaccination with SLA or recombinant leishmanial
and IL-12 protein was sufficient for the protection of sus-
ceptible BALB/c mice against challenge with 
 
L. major
 
 at 2
but not 12 wk after vaccination (9). To compare CpG
ODN with IL-12 protein as a vaccine adjuvant with a
heat-killed preparation of leishmanial Ag for long-term im-
munity, BALB/c mice were vaccinated and boosted with
ALM alone, ALM plus IL-12 protein, ALM plus CpG
ODN, or normal saline and infected 2 or 12 wk later.
Consistent with previous reports (9, 24, 25), mice vacci-
nated with ALM plus CpG ODN or ALM plus IL-12 pro-
tein were able to control the infection when challenged in
the opposite footpad 2 wk after vaccination (Fig. 1 A). In
contrast, mice vaccinated with ALM alone or with normal
saline developed ulcerations and were killed 3–4 wk after
infection. Mice vaccinated with ALM plus CpG ODN but
not ALM plus IL-12 protein were able to control the infec-
tion when challenged 12 wk after vaccination (Fig. 1 B).
Moreover, in the same experiment, mice that received
ALM plus CpG ODN were able to sustain control of in-
fection up to 3 mo after challenge. The control of infection
after ALM plus CpG ODN vaccination was comparable to
or better than that in mice treated with anti–IL-4 (an addi-
tional positive control) at the time of infection (Fig. 1 C).
To compare the protection from CpG ODN to that
elicited by a DNA vaccine, an additional group of mice
was given a cocktail of DNA plasmids encoding the leish-
manial Ag LACK, LmSTI1, and TSA previously shown to
elicit long-term protection (Fig. 1 D). Mice vaccinated
with ALM plus CpG ODN were equally able to control
infection, as measured by footpad swelling, as mice vacci-
nated with the DNA vaccine. To verify that CpG ODN
alone had no protective effect, mice vaccinated and
boosted only with CpG ODN were not protected when
challenged 12 wk after vaccination (Fig. 1 D). In addi-
tional experiments, mice vaccinated with CpG ODN
alone or ALM plus control ODN (without CpG) were not
able to control infection when challenged 2 wk after boost
(unpublished data).
 
Vaccination with ALM plus CpG ODN Confers Durable
Protection Against L. major in B6 Mice.
 
In contrast to the
BALB/c model, it has been demonstrated that vaccination
with ALM plus IL-12 confers durable protection against le-
sion development in the innately resistant B6 mouse (11).
As previously noted, the route and dose of infection in the
B6 mouse differ from those in the BALB/c mouse, offering 
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another model to assess the utility of CpG ODN as a vac-
cine adjuvant. B6 mice were vaccinated with ALM alone,
ALM plus IL-12, ALM plus CpG ODN, or normal saline
and then challenged intradermally in both ears 2 or 12 wk
after the boost (Fig. 2). Mice vaccinated with ALM plus
CpG ODN or IL-12 protein developed minimal lesions
when challenged 2 or 12 wk after vaccination (Fig. 2, A
and B). As a control in a separate experiment, mice given
CpG ODN alone at the time of vaccination and boost
were not protected and developed lesions comparable to
those of nonvaccinated mice when challenged 2 wk after
the boost (Fig. 2 C). Finally, in an additional experiment
(Fig. 2 D), the durability of ALM plus CpG ODN vaccina-
tion was comparable to that of DNA vaccination in elicit-
ing protection when challenged 12 wk after vaccination.
Mice Vaccinated with ALM plus CpG ODN Have a Reduc-
tion in Parasite Burden Compared with ALM plus IL-12 Protein
after Infectious Challenge with L. major. To determine
whether the reduction in footpad swelling (BALB/c mice)
or dermal lesions (B6 mice) previously shown correlated
with a decrease in parasite burden, mice in each of the vac-
cine groups were killed 4 wk after infection and parasite
burden was assessed. First, BALB/c mice vaccinated with
ALM plus CpG ODN had a 40-fold decrease in the para-
site burden from draining the LN of mice infected 12 wk
after vaccination compared with other groups (1.6   103 in
the ALM plus CpG ODN group compared with 6.3   104
in the saline group and 1.3   105 in the ALM group). ALM
plus CpG ODN–vaccinated mice were the only group that
was significantly different (P   0.05) from control saline-
Figure 1. Footpad swelling of BALB/c mice after in-
fection with L. major 2 or 12 wk after vaccination.
Mice (n    6–8 per group) were immunized in the
footpad and boosted 2 wk later with ALM, ALM plus
IL-12, ALM plus CpG ODN, or normal saline. Mice
were then challenged in the contralateral footpad with
105 L. major (A) 2 or (B) 12 wk after the boost and
footpad swelling measurements were recorded weekly.
These data are representative of three independent ex-
periments. (C) As a positive control in the same exper-
iment, a group of naive mice (n   6) was administered
anti–IL-4 3 d before, and at the time of, infection. (*)
Two mice in the anti–IL-4 treatment group were
killed 4 wk due to ulceration. (D) In a separate experi-
ment, mice were immunized with CpG ODN alone,
ALM, ALM plus CpG ODN, a cocktail of DNA plas-
mids encoding different leishmanial Ag, or normal sa-
line (n   6–8 per group). Challenge was then done 12
wk after the boost. Data represent the mean size of the
individual footpads   SEM.
Figure 2. Ear lesion size of B6 mice after infection
with L. major 2 or 12 wk after vaccination. Mice (n  
6–8 per group) were immunized and boosted 2 wk
later with ALM, ALM plus IL-12, ALM plus CpG
ODN, or normal saline in the footpad. Mice were
challenged (A) 2 or (B) 12 wk after the boost by intra-
dermal inoculation of 500 L. major metacyclic promas-
tigotes in both ears, and lesion diameter was moni-
tored. These data are representative of three
independent experiments. (C) In a separate experi-
ment, mice were vaccinated with CpG ODN, ALM,
ALM plus CpG ODN, or normal saline and then chal-
lenged 2 wk after the boost. (D) In another experi-
ment, mice were immunized with ALM plus CpG
ODN, a cocktail of DNA plasmids encoding different
leishmanial Ag, or normal saline and challenged 12 wk
after the boost. Data represent the mean lesion diame-
ter   SEM of four to eight mice, 8–16 ears per group.1569 Rhee et al.
vaccinated mice in terms of a decrease in parasite burden
(Fig. 3 A). Of note, there was also an  20-fold decrease in
the number of parasites in ALM plus CpG ODN compared
with ALM plus IL-12–vaccinated mice. Second, in the
low-dose dermal challenge model in B6 mice, both the
ALM plus IL-12 and ALM plus CpG ODN groups dem-
onstrated fewer parasites compared with the ALM and sa-
line groups (2.0   105 for ALM plus IL-12 and 3.2   104
for ALM plus CpG ODN vs. 1.5   106 for ALM and
2.5   106 for saline; Fig. 3 B). Most significantly, the mice
that received ALM plus CpG ODN had a greater than
2-log decrease in parasite burden compared with mice that
only received saline (P   0.05). Moreover, such mice had
approximately a sevenfold decrease in parasite burden com-
pared with ALM plus IL-12 protein–vaccinated mice. To-
gether, these data establish the enhanced biologic potency
of ALM plus CpG ODN compared with ALM plus IL-12
vaccination in terms of efficient parasite killing in both
mouse models.
ALM plus CpG ODN Immunization Induces CD4  T Cell
Production of IFN-  after Infection with L. major. Protec-
tion against L. major is dependent on Ag-specific production
of IFN-  from CD4  T cells. To test whether the adminis-
tration of ALM plus CpG ODN elicits Th1 responses, pro-
duction of IFN-  from CD4  T cells was assessed from
draining the LN 4 wk after infection from mice that were
challenged 12 wk after vaccination. As shown in Fig. 4,
CD4  T cells from BALB/c mice vaccinated with ALM
plus CpG ODN stimulated in vitro with macrophages
pulsed with L. major secreted substantially higher levels of
IFN-  compared with CD4  T cells from the other groups
(Fig. 4). Although not shown in this experiment, in previ-
ous studies (9, 10) as well as in the experiment shown in
Fig. 1 A, vaccination with ALM or recombinant leishmanial
protein plus IL-12 protein does not confer long-term pro-
tection or induce sustained Th1 responses in BALB/c mice.
ALM plus CpG ODN Sustains Protection Against L. major
up to 6 mo after Vaccination in B6 Mice. To further evaluate
the longevity of ALM plus CpG ODN immunization in
eliciting protection against L. major, B6 mice were vacci-
nated intradermally in the ear and then infected 6 mo later
in the opposite ear. First, to assess the immune correlates of
protection, we evaluated the immune responses of mice 6
mo after the last vaccination by measuring the frequency of
IFN- –producing T cells after a brief in vivo infection
(48 h) followed by in vitro stimulation. This method of in
vivo followed by in vitro Ag stimulation provides a sensi-
tive way to measure low level memory immune responses
after vaccination with ALM (11). As shown in Fig. 5 A, there
was a demonstrable number of both CD4  and CD8  T
cells producing IFN-  after stimulation with DC pulsed
with  L. major. In contrast, nonvaccinated mice demon-
strated very low frequencies of IFN- –producing CD4  or
CD8  T cells (0.1–0.2%). It was striking that the ALM plus
CpG ODN–vaccinated group had similar or higher fre-
quencies of CD4  and CD8  IFN- –producing cells than
the definitive positive control (previously infected mice
that had healed; unpublished data). To correlate these find-
ings with an infectious challenge, mice were injected with
L. major intradermally in the ear 6 mo after vaccination.
Mice that received ALM plus CpG ODN demonstrated lit-
tle or no pathology after challenge as assessed by lesion size
(Fig. 5 B). Furthermore, the degree of protection induced
by ALM plus CpG ODN was comparable to that in previ-
ously infected mice that had healed or mice that had been
vaccinated with a cocktail of plasmid DNA encoding re-
combinant leishmanial Ag (unpublished data).
CD8  T Cell Depletion at the Time of Vaccination Mitigates
Protection Conferred by Vaccination with ALM or Recombinant
Leishmanial Protein plus CpG ODN. We have previously
shown that the depletion of CD8  T cells at the time of
vaccination or infection abrogates protective immunity in
BALB/c mice vaccinated with plasmid DNA encoding
LACK Ag (7, 13) and B6 mice vaccinated with a cocktail
of DNA Ag (unpublished data). Because ALM plus CpG
ODN immunization was able to induce CD8  T cell re-
sponses 6 mo after vaccination (Fig. 5), the role of CD8  T
cells in mediating protection was determined by depleting
CD8  T cells in vivo at the time mice were vaccinated. In
these experiments, the depletion of CD8  T cells at the
time of vaccination rather than at the time of infection was
Figure 3. Parasite burden in
the draining LN and ears of in-
fected BALB/c and B6 mice af-
ter vaccination and infection. (A)
BALB/c mice were vaccinated
and then challenged 12 wk after
boost with L. major in the foot-
pad (groups shown in Fig. 1 B).
Parasite quantitation in the drain-
ing LN of three individual mice
was done 4 wk after challenge.
(B) B6 mice were vaccinated and
then challenged 12 wk after
boost with L. major in both ears
(groups shown in Fig. 2 B). Par-
asite loads in the ears were deter-
mined 4 wk after challenge from
four individual mice in each
group (n   8 ears). Results are
expressed as geometric mean  
SEM. *, P   0.05 when ALM
plus CpG ODN is compared
with saline-vaccinated mice.
Figure 4. Leishmania-spe-
cific production of IFN-  from
CD4   T cells after infection
with  L. major. BALB/c mice
were vaccinated and then chal-
lenged with L. major 12 wk after
boost. CD4  T cells were iso-
lated from the draining LN 4 wk
after challenge and stimulated in
culture with media alone, mac-
rophages, or macrophages plus
L. major. IFN-  levels were
measured 48 h later by ELISA of culture supernatants. Data are the mean
concentrations of triplicate assays   SD.1570 Leishmanial Ag plus CpG ODN Vaccination Confers Sustained Immunity
done to limit induction of Ag-specific CD8  T cells but
not limit the role of the endogenous repertoire of CD8  T
cells during the natural course of infection, which we have
recently shown to be important in mediating primary pro-
tection in the B6 mouse model (31). As shown in Fig. 6 A,
depletion of CD8  T cells at the time of vaccination with
ALM plus CpG ODN resulted in an increase in ear lesion
swelling compared with that in mice vaccinated with ALM
plus CpG ODN alone or treated with a control rat Ig Ab.
Because the peak number of parasites in the site is found
just before the onset of lesion development in the natural
course of the low-dose intradermal challenge model (12),
parasite loads were quantitated 4 wk after infection when
there was as yet little difference in the size of the dermal le-
sions between the anti-CD8–treated and control-treated
mice. There was, however, a 1–2-log increase in parasite
load in the ears and draining LN (Fig. 6 B) in ALM plus
CpG ODN–vaccinated mice treated with anti-CD8.
These findings suggest that CpG ODN induces CD8  T
cell responses by enhancing the processing of proteins con-
tained within the ALM. Because ALM is an autoclaved
preparation of whole L. major, it was of interest to perform
similar studies using a recombinant leishmanial protein to
provide additional evidence that CD8  T cells were impor-
tant in mediating protection using CpG ODN as a vaccine
adjuvant. In this regard, mice were immunized with CpG
ODN and a recombinant Trifusion protein comprising
three different leishmanial proteins in the presence or ab-
sence of CD8 depletion at the time of immunization.
These recombinant leishmanial proteins have been previ-
ously shown to confer protection in both mouse and pri-
mate models of L. major infection (11, 28–30, 32). As
shown in Fig. 7, B6 mice immunized with Trifusion pro-
tein plus CpG ODN had minimal lesions when challenged
with L. major 2 (Fig. 7 A) or 12 wk (Fig. 7 B) after vaccina-
tion. Similar to the results shown above, the treatment of
Trifusion plus CpG ODN–immunized mice with anti-
CD8 at the time of vaccination resulted in an increase in
the lesion size and parasite load (Fig. 7 C) after infection.
Finally, mice vaccinated with Trifusion DNA had minimal
ear lesions after infection 12 wk after immunization, which
was comparably altered by treatment with anti-CD8 at the
time of vaccination (unpublished data). Thus, vaccination
with either leishmanial DNA (7, 13) or leishmanial protein
or killed Ag plus CpG ODN induces long-term protection
against L. major in a CD8  T cell–dependent manner.
Discussion
This study demonstrates in two different mouse models
of L. major infection that CpG ODN provides long-term
Figure 5. Assessment of cellular immune responses and protection in
B6 mice 6 mo after vaccination. (A) IFN-   responses by CD4  and
CD8  T cells in B6 mice were assessed 6 mo after intradermal vaccination
with ALM plus CpG ODN or saline. Draining LN cells were obtained
48 h after intradermal injection of metacyclic promastigotes and SLA into the
nonvaccinated ear and 24 h after in vitro restimulation with uninfected
DC or infected DC (three mice per group, six LN). Analyses are gated on
CD3  cells. Numbers represent the percentage of CD4  or CD8  T cells
positive for IFN- . Nonvaccinated mice were included as negative con-
trols. (B) In the same experiment, mice vaccinated with ALM plus CpG
ODN were challenged 6 mo after boost with L. major in the ear opposite
from which they were vaccinated and ear lesions were monitored. Data
represent the mean lesion diameter   SEM of six to eight mice.
Figure 6. Effect of CD8  T cell depletion on lesion development and
parasite load in mice vaccinated with ALM plus CpG ODN. (A) Mice
(n   6–8 per group) were immunized and boosted 2 wk later with ALM,
ALM plus CpG ODN, or normal saline in the footpad. In some
groups, mice were treated 1 d before, and at the time of, vaccination
with anti-CD8 (2.43) or rat Ig Ab. Mice were then challenged 2 wk later
in the ear and monitored as described in Fig. 2. (B) Parasite loads in the
ears and draining LN were determined 4 wk after challenge from four
mice in each group (n   8 ears) or pooled draining LN from four mice.
Results for the parasite load in the ears are expressed as geometric
mean   SEM. *, P   0.05 in comparing parasites per ear harvested from
ALM plus CpG ODN–vaccinated mice depleted of CD8  T cells.1571 Rhee et al.
protection when used as a vaccine adjuvant with either
ALM or recombinant leishmanial protein. In addition, sim-
ilar to our previous studies with DNA vaccines, CpG
ODN conferred more potent and durable protection when
compared with IL-12 protein as an adjuvant with ALM.
These data strongly suggest that a heat-killed Ag and/or a
recombinant protein vaccine can be useful for inducing du-
rable immunity for diseases requiring cellular immune re-
sponses depending on the adjuvant used.
Our data demonstrating that ALM or Trifusion protein
plus CpG ODN provides long-term protection are in con-
trast to previous studies using CpG ODN as a vaccine adju-
vant with other leishmanial Ag preparations. In the study
by Stacey and Blackwell (24), partial protection was dem-
onstrated in BALB/c mice infected 6 wk or 6 mo after vac-
cination, but the quality of protection at any time after vac-
cination was moderate because all of the mice developed
significant footpad swelling. Similarly, Walker et al. (25)
demonstrated that the effects of CpG ODN as an adjuvant
were partial and limited, as protection was demonstrated in
only 40% of BALB/c mice challenged 3 wk after vaccina-
tion. The greater efficacy of the leishmanial protein plus
CpG ODN in our study may be due to several factors.
First, the leishmanial Ag used in the other studies was a
preparation of SLA, which might be less immunogenic
than ALM, a clinical grade Ag that has been used in human
vaccine trials against L. major (33, 34). Second, the parasite
dose and strain differed in our studies compared with the
other studies. Third, the CpG ODN sequence we used was
different than that used in one of the previous studies
showing partial long-term immunity. Nevertheless, the re-
sults presented here showing that CpG ODN provide
long-term protection have been repeated multiple times in
both BALB/c and B6 mouse models of leishmania infec-
tion with consistent results and little variability.
With regard to the mechanism by which CpG ODN
mediate their function in vivo and why they are better
than IL-12 protein as a vaccine adjuvant, their role in en-
hancing APC function needs to be considered. At the
APC level, CpG ODN through toll-like receptor 9, aug-
ments both the activation and maturation of DC as well as
the induction of proinflammatory cytokines (35). Thus, in
comparison to the relatively short-lived effect of exoge-
nous IL-12 protein as an adjuvant, the endogenous pro-
duction of IL-12, IL-18, and other soluble mediators from
activated DC induced by CpG ODN are likely to result in
a more physiologic cognate interaction between the DC
and T cell, resulting in both a qualitatively and quantita-
tively different type of CD4  and CD8  T cell response.
These data highlight the potential importance of targeting
DC, especially for vaccines against diseases requiring cellu-
lar immune responses.
In terms of immune correlates of protection, it is well es-
tablished that CpG ODN are potent inducers of Th1 re-
sponses, which is consistent with our findings that mice
vaccinated with ALM plus CpG ODN had striking en-
hancement in the frequency and production of IFN-  from
CD4  T cells 6 mo after vaccination in B6 mice (Fig. 5)
and after infection in BALB/c mice, respectively (Fig. 4).
Moreover, an additional possibility relating to the effective-
ness of CpG ODN as a vaccine adjuvant compared with
IL-12 protein in the BALB/c and B6 models is the role of
CD8  T cells. As previously mentioned, CD8  T cell re-
sponses are not seen in vaccination with recombinant leish-
manial protein plus IL-12 but have an important role in
maintaining the protection elicited by DNA vaccination (7,
13). In this regard, CpG ODN have been shown to elicit
CD8  T cell responses in mice when given with a protein
Ag such as OVA (20). Thus, our findings that there were
significant frequencies of Ag-specific CD8  IFN-   cells in
B6 mice 6 mo after vaccination with ALM plus CpG
ODN and that the depletion of CD8  T cells at the time of
vaccination enhances the size of the lesions and the parasite
load in B6 mice, provide compelling evidence for the im-
portance of CD8  T cells in mediating long-term immu-
nity. Furthermore, the data showing that lesion develop-
Figure 7. Effect of CD8 depletion in mice vaccinated with recombi-
nant leishmanial protein plus CpG ODN. Mice (n   6–8 per group) were
immunized and boosted 2 wk later with Trifusion protein, Trifusion pro-
tein plus CpG ODN, or normal saline (nonvaccinated) in the footpad. In
some groups, mice were treated 1 d before, and at the time of, vaccina-
tion with anti-CD8 (2.43) or rat Ig control Ab. Mice were challenged (A)
2 or (B) 12 wk after the last immunization in the ear and lesion size was
monitored as described in Fig. 2. (C) Parasite loads in the ears from mice
challenged 2 wk after vaccination were determined as described in Fig. 6.
Tri, Trifusion; *, P   0.05 in comparing parasites per ear harvested from
Trifusion plus CpG ODN–vaccinated mice depleted of CD8  T cells.1572 Leishmanial Ag plus CpG ODN Vaccination Confers Sustained Immunity
ment is altered in B6 mice immunized with a recombinant
leishmanial protein plus CpG ODN depleted of CD8  T
cells at the time of vaccination provides additional support
for CpG ODN inducing CD8  T cell responses with a de-
fined parasitic protein Ag. Finally, although lesion size in
leishmanial Ag plus CpG ODN–vaccinated mice depleted
of CD8  T cells was increased, these mice had demonstra-
bly smaller lesions than control vaccinated mice. This is
consistent with the induction of both CD4  and CD8  T
cells by such a vaccine. Together, these data suggest that
vaccines that elicit both CD4  and CD8  T cell responses
are sufficient to confer long-term protection against L. ma-
jor in mice.
Although the vaccine approach described here poten-
tially has immediate clinical use because ALM is already a
widely tested vaccine Ag in humans, it remains to be deter-
mined whether the effects of CpG ODN on the cellular
immune response in humans will be comparable to those
observed in mice. One encouraging recent report related to
this issue showed that there was a decrease in lesion size af-
ter infectious challenge with L. major in primates vacci-
nated with a killed preparation of leishmanial Ag and a spe-
cific type of CpG ODN compared with vaccination with
Ag alone (36). To conclude, it is worth noting that the his-
torical standard for effective vaccination against L. major in
humans is leishmaniazation (attenuated live infection).
Moreover, the fact that previous infection to L. major con-
fers life-long protection in humans and that there is evi-
dence for the persistence of parasitic Ag raises the critical is-
sue of whether the induction of potent CD4  and CD8  T
cell responses induced after DNA or a killed and/or re-
combinant leishmanial Ag plus CpG ODN will be suffi-
cient to confer life-long protection in humans. This dis-
tinction between the apparent lack of an Ag requirement to
maintain cellular immune memory for CD4  and CD8  T
cell responses for nonliving vaccines versus the potential re-
quirement of Ag for mediating biologic protection will be
the critical determinant in whether specific vaccines will be
successful over the course of a lifetime against many infec-
tions requiring cellular immunity in humans.
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